Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study

作者：Mirko Farina, Simona Bernardi, Michele Malagola, Alessandro Re, Eugenio Galli, Marcello Riva, Ilaria Cutini, Alessandro Leoni, Massimo Martino, Silvia Ferrari, Giorgia Battipaglia, Mattia Novo, Maurizio Musso, Giovanni Grillo, Stella Santarone, Mauro Krampera, Andrea Aroldi, Nicola Polverelli, Luca Arcaini, Besjana Xhahysa, Daniele Avenoso, Maria Chiara Tisi, Patrizia Chiusolo, Domenico Russo · 发表于：Bone Marrow Transplantation · 年份：2025 · DOI：10.1038/s41409-025-02529-x · 被引用次数：9 · 研究领域：CAR-T cell therapy research、Acute Lymphoblastic Leukemia research

Chimeric Antigen Receptor T cell (CAR-T) therapy is a cutting-edge immunotherapy approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma. Despite its remarkable efficacy, recent concerns have emerged regarding the risk of secondary neoplasms [ 1 , 2 , 3 ], particularly secondary myeloid malignancies (SMNs) [ 3 ].